Drug name
Last update: Jul 2026lepetegravir + lenacapavir pacfosacil (GS-1720+GS-4182)
Developer(s)
Drug information
Not provided
lepetegravir + lenacapavir pacfosacil
investigational
Small molecule
INSTI+capsid inhibitor
The candidate HIV treatment regimen based on the co-administration of GS-1720+GS-4182 is investigated as once-weekly oral regimen in people with HIV. The trials using GS-1720 and/or GS-4182 were put on clinical hold in June 2025, because some participants developed low levels of CD4+T-cells and reduced count of total white blood cells.
investigational
investigational
Therapeutic area(s)
- HIV
- Treatment
Administration route
Oral
Associated long-acting platforms
Oral solid form
Use of drug
- Self-administered
- Weekly
Dosage
GS-1720 (650 mg tablet) and GS-4182 (300 mg tablet) (or the fixed-dose combination)
GS-1720 (650 mg tablet) and GS-4182 (300 mg tablet)
investigational dosing is ongoing
Not provided
Not provided
Associated compounds, formulations and regimens
Lenacapavir pacfosacil (GS-4182)
lepetegravir (GS-1720)
Associated technologies
Not provided
Additional information
Developer(s)
Gilead
Drug structure
Scale-up and manufacturing prospects
Undisclosed
Undisclosed
Undisclosed
Undisclosed
Excipients & delivery device(s)
Not provided
Not provided
Not provided
No delivery device
Safety, Efficacy and Evidence Summary
Not provided
Not provided
Not provided
Not provided
There are either no relevant patents or these were not yet submitted to LAPaL